Pharmacologicstudies demonstrate that the PPARδ selective-agonist (GW501516) attenuatedweight gain and insulin resistance in mice fed with high-fat diets [10] and increased HDL-C whilelowering tryglyceride levels and insulin in obese rhesus monkeys [11].Furthermore, preclinical studies revealed that PPARδ agonists diminished metabolicderangements and obesity through increasing lipid combustion in skeletal muscle[12]. Here, INS is linked to obesity disorder.